{"document_type": "article", "snippet": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html", "subsection_name": null, "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-05T00:00:00Z", "word_count": "1668", "slideshow_credits": null, "news_desk": "Business", "byline": {"original": "By ANDREW POLLACK and SABRINA TAVERNISE", "person": [{"role": "reported", "lastname": "POLLACK", "rank": 1, "organization": "", "firstname": "Andrew"}, {"role": "reported", "lastname": "TAVERNISE", "rank": 2, "organization": "", "firstname": "Sabrina"}]}, "abstract": "Valeant Pharmaceuticals International has outperformed its rivals in industry due in large part to executive J Michael Pearson's aggressive practice of buying up existing drugs and then raising prices on them significantly, but tactic has drawn ire of consumers and attention of regulators; focus of regulators has many in industry worried, as many companies employ similar tactic, though not to extreme Valeant does.", "keywords": [{"value": "Drugs (Pharmaceuticals)", "rank": "1", "name": "subject", "is_major": "Y"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "2", "name": "organizations", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "rank": "3", "name": "persons", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "rank": "4", "name": "subject", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "5", "name": "subject", "is_major": "N"}], "print_page": "1", "multimedia": [{"subtype": "wide", "legacy": {"wideheight": "126", "wide": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg", "widewidth": "190"}, "type": "image", "width": 190, "height": 126, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg"}, {"subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg"}, "type": "image", "width": 600, "height": 400, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg"}, {"subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "type": "image", "width": 75, "height": 75, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg"}], "lead_paragraph": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "headline": {"print_headline": "A Drug Company&#8217;s Price Tactics Pinch Insurers and Consumers", "main": "Valeant\u2019s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers"}, "_id": "5610f8bd38f0d85cd9760cec"}